Enhanced platelet activity and thrombosis in a murine model of type I diabetes are partially insulin-like growth factor 1-dependent and phosphoinositide 3-kinase-dependent

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 5, 2013, Pages 919-929

  Stolla, M C ^a   Li, D ^a   Lu, L ^b   Woulfe, D S ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERROUS CHLORIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLUCOSE; INTEGRIN; INTEGRIN ALPHA2B BETA3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR 4; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DISEASE MODEL; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; THROMBOCYTE ACTIVATION;

ANIMALS; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STREPTOZOCIN; THROMBOSIS;

EID: 84877917989     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12170     Document Type: Article

References (48)

1. Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 2010; 7: 251-9.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
3. Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, Adamson U, Henriksson P, Wallen NH, Jorneskog G. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res 2010; 126: e225-31.
4. Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 2007; 7: 223-7.
5. Westrick RJ, Eitzman DT. Plasminogen activator inhibitor-1 in vascular thrombosis. Curr Drug Targets 2007; 8: 966-1002.
6. Neubauer H, Setiadi P, Gunesdogan B, Pinto A, Borgel J, Mugge A. Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in type 2 diabetes. Diabet Med 2010; 27: 384-90.
7. Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P, Wallen NH. Enhanced P-selectin expression and increased soluble CD40 ligand in patients with type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004; 47: 537-40.
8. Anfossi G, Russo I, Trovati M. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol 2008; 6: 313-28.
9. Whinna HC. Overview of murine thrombosis models. Thromb Res 2008; 122(Suppl. 1): S64-9.
10. Zhu W, Li W, Silverstein RL. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36. Blood 2012; 119: 6136-44.
11. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest 2004; 113: 441-50.
12. Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood 2004; 104: 1703-10.
13. O'Brien KA, Stojanovic-Terpo A, Hay N, Du X. An important role for Akt3 in platelet activation and thrombosis. Blood 2011; 118: 4215-23.
14. Ishiki M, Klip A. Minireview: recent developments in the regulation of glucose transporter-4 traffic: new signals, locations, and partners. Endocrinology 2005; 146: 5071-8.
15. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB III, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001; 292: 1728-31.
16. Worster DT, Schmelzle T, Solimini NL, Lightcap ES, Millard B, Mills GB, Brugge JS, Albeck JG. Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. Sci Signal 2012; 5: ra19.
17. Cheng SM, Ho TJ, Yang AL, Chen IJ, Kao CL, Wu FN, Lin JA, Kuo CH, Ou HC, Huang CY, Lee SD. Exercise training enhances cardiac IGFI-R/PI3K/Akt and Bcl-2 family associated pro-survival pathways in streptozotocin-induced diabetic rats. Int J Cardiol 2012; in press.
18. Chen HS, Wu TE, Hsiao LC, Lin SH. Interaction between glycaemic control and serum insulin-like growth factor 1 on the risk of retinopathy in type 2 diabetes. Eur J Clin Invest 2012; 42: 447-54.
19. Miller EC, Capps BE, Sanghani RR, Clemmons DR, Maile LA. Regulation of igf-I signaling in retinal endothelial cells by hyperglycemia. Invest Ophthalmol Vis Sci 2007; 48: 3878-87.
20. Maile LA, Capps BE, Ling Y, Xi G, Clemmons DR. Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I. Endocrinology 2007; 148: 2435-43.
21. Calkin AC, Drew BG, Ono A, Duffy SJ, Gordon MV, Schoenwaelder SM, Sviridov D, Cooper ME, Kingwell BA, Jackson SP. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009; 120: 2095-104.
22. Randriamboavonjy V, Fleming I. The role of calpain in diabetes-associated platelet hyperactivation. Adv Pharmacol 2010; 59: 235-57.
23. Zhu Z, Zhou H, Yu X, Chen L, Zhang H, Ren S, Wu Y, Luo D. Potential regulatory role of calsequestrin in platelet Ca(2+) homeostasis and its association with platelet hyperactivity in diabetes mellitus. J Thromb Haemost 2012; 10: 116-24.
24. Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, Akkerman JW. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26: 417-22.
25. 2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 2004; 279: 3254-64.
26. Hunter RW, Hers I. Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function. J Thromb Haemost 2009; 7: 2123-30.
27. Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway. Blood 2007; 110: 4243-52.
28. Kim S, Garcia A, Jackson SP, Kunapuli SP. Insulin-like growth factor-1 regulates platelet activation through PI3-Kalpha isoform. Blood 2007; 110: 4206-13.
29. Wong JH, Dukes J, Levy RE, Sos B, Mason SE, Fong TS, Weiss EJ. Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patterns. J Clin Invest 2008; 118: 2969-78.
30. Landau D, Eshet R, Troib A, Gurman Y, Chen Y, Rabkin R, Segev Y. Increased renal Akt/mTOR and MAPK signaling in type I diabetes in the absence of IGF type 1 receptor activation. Endocrine 2009; 36: 126-34.
31. Akin I, Bufe A, Eckardt L, Reinecke H, Senges J, Richardt G, Kuck KH, Schneider S. Nienaber, CA; DES.DE STudy Group. Comparison of outcomes in patients with insulin-dependent versus non-insulin dependent diabetes mellitus receiving drug-eluting stents (from the first phase of the prospective multicenter German DES.DE registry). Am J Cardiol 2010; 106: 1201-7.
32. Shukla SD, Kansra SV, Reddy MA, Shukla SM, Klachko DM, Sturek M. Platelets from diabetic pigs exhibit hypersensitivity to thrombin. Comp Med 2008; 58: 481-4.
33. Canobbio I, Stefanini L, Cipolla L, Ciraolo E, Gruppi C, Balduini C, Hirsch E, Torti M. Genetic evidence for a predominant role of PI3Kbeta catalytic activity in ITAM- and integrin-mediated signaling in platelets. Blood 2009; 114: 2193-6.
34. Hirsch E, Bosco O, Tropel P, Laffargue M, Calvez R, Altruda F, Wymann M, Montrucchio G. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001; 15: 2019-21.
35. Schoenwaelder SM, Ono A, Sturgeon S, Chan SM, Mangin P, Maxwell MJ, Turnbull S, Mulchandani Anderson K, Kaufenstein G, Rewcastle GW, Kendall J, Gachet C, Salem HH, Jackson SP. Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha IIb beta 3 adhesive function in platelets. J Biol Chem 2007; 282: 28648-58.
36. Cosemans JM, van Kruchten R, Olieslagers S, Schurgers LJ, Verheyen FK, Munnix IC, Waltenberger J, Angelillo-Scherrer A, Hoylaerts MF, Carmeliet P, Heemskerk JW. Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization. J Thromb Haemost 2010; 8: 1797-808.
37. Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, Daniel JL, Kunapuli SP. The role of PI 3-K{beta} in glycoprotein VI-mediated akt activation in platelets. J Biol Chem 2009; 284: 33763-72.
38. Schneider HJ, Friedrich N, Klotsche J, Schipf S, Nauck M, Volzke H, Sievers C, Pieper L, Marz W, Wittchen HU, Stalla GK, Wallaschofski H. Prediction of incident diabetes mellitus by baseline IGF1 levels. Eur J Endocrinol 2011; 164: 223-9.
39. Xi G, Shen X, Maile LA, Wai C, Gollahon K, Clemmons DR. Hyperglycemia enhances IGF-I-stimulated Src activation via increasing Nox4-derived reactive oxygen species in a PKCzeta-dependent manner in vascular smooth muscle cells. Diabetes 2012; 61: 104-13.
40. Dills DG, Moss SE, Klein R, Klein BE. Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes 1991; 40: 1725-30.
41. Flyvbjerg A, Marshall SM, Frystyk J, Rasch R, Bornfeldt KE, Arnqvist H, Jensen PK, Pallesen G, Orskov H. Insulin-like growth factor I in initial renal hypertrophy in potassium-depleted rats. Am J Physiol 1992; 262: F1023-31.
42. Chao W, Matsui T, Novikov MS, Tao J, Li L, Liu H, Ahn Y, Rosenzweig A. Strategic advantages of insulin-like growth factor-I expression for cardioprotection. J Gene Med 2003; 5: 277-86.
43. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 1995; 92: 8031-5.
44. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, Anker SD, Poole-Wilson PA, Ranke MB, Dietz R. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-7.
45. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Sacca L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-14.
46. Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM, Treuer AV, Lamirault G, Dulce R, Hurtado M, Song Y, Block NL, Rick F, Klukovits A, Hu Q, Varga JL, Schally AV, Hare JM. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci USA 2010; 107: 2604-9.
47. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001; 104: 330-5.
48. Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton R, Galasso G, Birnbaum MJ, Walsh K, Sessa WC. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 2005; 115: 2119-27.